S. Andersson

Dosage of X‐linked Toll‐like receptor 8 determines gender differences in the development of systemic lupus erythematosus

J. Kearney, T. Imanishi‐Kari, L. Fernandez, 2014, European journal of immunology.

Fitusiran, an Investigational siRNA Therapeutic Targeting Antithrombin for the Treatment of Hemophilia: First Results from a Phase 3 Study to Evaluate Efficacy and Safety in People with Hemophilia a or B without Inhibitors (ATLAS-A/B)

L. Frenzel, O. Stasyshyn, S. Pipe, 2021, Blood.

Fitusiran, an RNAi Therapeutic Targeting Antithrombin to Restore Hemostatic Balance in Patients with Hemophilia a or B with or without Inhibitors: Management of Acute Bleeding Events

C. Négrier, S. Pipe, M. Ragni, 2019, Blood.

Fitusiran prophylaxis in people with severe haemophilia A or haemophilia B without inhibitors (ATLAS-A/B): a multicentre, open-label, randomised, phase 3 trial.

L. Frenzel, O. Stasyshyn, S. Pipe, 2023, The Lancet. Haematology.

Efficacy and safety of fitusiran prophylaxis in people with haemophilia A or haemophilia B with inhibitors (ATLAS-INH): a multicentre, open-label, randomised phase 3 trial

G. Young, S. Rangarajan, C. Ross, 2023, The Lancet.

Efficacy and Safety of Fitusiran Prophylaxis, an siRNA Therapeutic, in a Multicenter Phase 3 Study (ATLAS-INH) in People with Hemophilia A or B, with Inhibitors (PwHI)

R. Wu, G. Young, S. Rangarajan, 2021, Blood.